ACHN up +22.55% percent Today $ACHN High is at 12.75 and the Low 10.67 with current volume of 14,543,292.
Recent News posted below.
Achillion Pharmaceuticals ACHN other info.
http://investorshangout.com/Achillion-Pharmac...CHN-53213/
ACHN Achillion Pharmaceuticals Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 1 hr 24 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.66 (+0.46), GILD: 107.73 (+1.28), ACHN: 12.42 (+2.31), MRK: 58.84 (-0.50), ABBV: 63.65 (+2.15), BMY: 58.59 (+0.27)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 1 hr 58 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.73 (+1.28), ACHN: 12.42 (+2.31), RGLS: 22.96 (+0.88), ABBV: 63.66 (+2.16)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 12.42 (+2.31)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.42 (+2.31)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 107.73 (+1.28), ACHN: 12.42 (+2.31)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.01 (-0.01), HSKA: 15.84 (-0.06), ACHN: 12.42 (+2.31), AMAG: 34.59 (-0.36)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 6.95 (-0.05), ALIM: 5.00 (-0.06), ACHN: 12.42 (+2.31), FNHC: 26.38 (+0.24), ARCP: 8.50 (-0.29), CKEC: 28.20 (+0.30), JAXB: 11.91 (+0.22), PCLN: 1,107.00 (+12.39), TESO: 16.01 (-0.05)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 74.99 (-0.61), PLUG: 5.27 (-0.03), NYMX: 0.68 (-0.07), INTC: 33.32 (-0.26), FOX: 33.13 (-0.11), SAPE: 24.66 (-0.01), GERN: 2.23 (-0.10), ACHN: 12.42 (+2.31), FOXA: 34.57 (-0.04), ODP: 6.50 (unch), ARCP: 8.50 (-0.29), MSFT: 49.05 (+0.37), GRPN: 7.46 (-0.04), AAPL: 108.94 (-0.07)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 12.42 (+2.31)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.29 (+3.45), CYTX: 0.39 (-0.04), ACHN: 12.42 (+2.31), INCY: 70.15 (+0.83), SRPT: 15.98 (-0.14)
Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 12.42 (+2.31)
Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 12.42 (+2.31)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 107.70 (+1.25), CLVS: 58.86 (+0.55), ARWR: 6.39 (+0.33), ACHN: 12.42 (+2.31), MRK: 58.84 (-0.50), RTRX: 10.04 (-0.34), RGLS: 22.96 (+0.88), EPZM: 23.19 (-0.56), AGIO: 77.34 (+5.28), RMTI: 10.41 (-0.14), ARNA: 4.30 (+0.04), KERX: 16.46 (-0.27)
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 387.19 (+3.03), ACHN: 12.42 (+2.31), CVS: 89.10 (+0.72), N: 109.80 (+0.72), PAY: 37.05 (+0.49)
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 107.70 (+1.25), ACHN: 12.42 (+2.31), MRK: 58.84 (-0.50), ABBV: 63.66 (+2.16)
Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 25.13 (-0.74), FBHS: 42.87 (+0.07), ACHN: 12.42 (+2.31), KBH: 16.63 (+0.29), HOV: 3.94 (+0.17)
November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 12.42 (+2.31)
Recent News posted below.
Achillion Pharmaceuticals ACHN other info.
http://investorshangout.com/Achillion-Pharmac...CHN-53213/
ACHN Achillion Pharmaceuticals Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 1 hr 24 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.66 (+0.46), GILD: 107.73 (+1.28), ACHN: 12.42 (+2.31), MRK: 58.84 (-0.50), ABBV: 63.65 (+2.15), BMY: 58.59 (+0.27)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - 1 hr 58 mins ago
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.73 (+1.28), ACHN: 12.42 (+2.31), RGLS: 22.96 (+0.88), ABBV: 63.66 (+2.16)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline - ACHN: 12.42 (+2.31)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.42 (+2.31)
Why Achillion Pharmaceuticals, Inc. Stock Launched 18% Higher in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 8:40AM CST
ACHN data by YCharts What: Shares of Achillion Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat hepatitis C and other chronic bacterial infections, launched higher by 18% during the month...
GILD: 107.73 (+1.28), ACHN: 12.42 (+2.31)
Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.01 (-0.01), HSKA: 15.84 (-0.06), ACHN: 12.42 (+2.31), AMAG: 34.59 (-0.36)
Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 6.95 (-0.05), ALIM: 5.00 (-0.06), ACHN: 12.42 (+2.31), FNHC: 26.38 (+0.24), ARCP: 8.50 (-0.29), CKEC: 28.20 (+0.30), JAXB: 11.91 (+0.22), PCLN: 1,107.00 (+12.39), TESO: 16.01 (-0.05)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 74.99 (-0.61), PLUG: 5.27 (-0.03), NYMX: 0.68 (-0.07), INTC: 33.32 (-0.26), FOX: 33.13 (-0.11), SAPE: 24.66 (-0.01), GERN: 2.23 (-0.10), ACHN: 12.42 (+2.31), FOXA: 34.57 (-0.04), ODP: 6.50 (unch), ARCP: 8.50 (-0.29), MSFT: 49.05 (+0.37), GRPN: 7.46 (-0.04), AAPL: 108.94 (-0.07)
Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 12.42 (+2.31)
Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 99.29 (+3.45), CYTX: 0.39 (-0.04), ACHN: 12.42 (+2.31), INCY: 70.15 (+0.83), SRPT: 15.98 (-0.14)
Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 12.42 (+2.31)
Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 12.42 (+2.31)
Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 107.70 (+1.25), CLVS: 58.86 (+0.55), ARWR: 6.39 (+0.33), ACHN: 12.42 (+2.31), MRK: 58.84 (-0.50), RTRX: 10.04 (-0.34), RGLS: 22.96 (+0.88), EPZM: 23.19 (-0.56), AGIO: 77.34 (+5.28), RMTI: 10.41 (-0.14), ARNA: 4.30 (+0.04), KERX: 16.46 (-0.27)
Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 387.19 (+3.03), ACHN: 12.42 (+2.31), CVS: 89.10 (+0.72), N: 109.80 (+0.72), PAY: 37.05 (+0.49)
Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 107.70 (+1.25), ACHN: 12.42 (+2.31), MRK: 58.84 (-0.50), ABBV: 63.66 (+2.16)
Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 25.13 (-0.74), FBHS: 42.87 (+0.07), ACHN: 12.42 (+2.31), KBH: 16.63 (+0.29), HOV: 3.94 (+0.17)
November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 12.42 (+2.31)
